Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Post by skyhigh123on Jul 13, 2018 4:10am

217 Views

Post# 28310638

posted this instead of the sh@t that’s being posted

InterMune (NASDAQ:ITMN) sold worldwide development and commercialization rights to danoprevir to its development partner Roche (OTCQX:RHHBY) for $175 million in cash. The partners also ended their HCV research collaboration agreement entered into in 2005. InterMune will put all its resources into its lead product pirfenidone, its investigational treatment for idiopathic pulmonary fibrosis.

“After conducting a careful review of our strategy and financial position, we have decided to divest our rights to danoprevir to Roche, says Dan Welch, chairman and CEO of InterMune. “We are now in a very strong financial position that provides us with the resources and flexibility to maximize the value of pirfenidone, our largest and nearest-term value creation opportunity.”
Update Roche paid $8.3 Billion for this IPF Drug

Bullboard Posts

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project